NasdaqGS:ALNY

Stock Analysis Report

Executive Summary

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Alnylam Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALNY has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.3%

ALNY

1.9%

US Biotechs

0.5%

US Market


1 Year Return

35.0%

ALNY

8.1%

US Biotechs

12.8%

US Market

Return vs Industry: ALNY exceeded the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: ALNY exceeded the US Market which returned 12.8% over the past year.


Shareholder returns

ALNYIndustryMarket
7 Day-1.3%1.9%0.5%
30 Day15.0%11.6%4.3%
90 Day14.9%7.9%8.0%
1 Year35.0%35.0%9.1%8.1%15.3%12.8%
3 Year88.4%88.4%14.0%10.5%48.3%38.7%
5 Year1.0%1.0%5.2%0.3%62.6%44.5%

Price Volatility Vs. Market

How volatile is Alnylam Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

6.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ALNY ($90.85) is trading above our estimate of fair value ($17.05)

Significantly Below Fair Value: ALNY is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALNY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ALNY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALNY is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

47.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALNY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALNY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALNY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALNY's revenue (52.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ALNY's revenue (52.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALNY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Alnylam Pharmaceuticals performed over the past 5 years?

-26.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALNY has high quality earnings.

Growing Profit Margin: ALNY's current net profit margins (-485.7%) are higher than last year (-754.1%).


Past Earnings Growth Analysis

Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of -26% per year.

Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (69.3%).


Return on Equity

High ROE: ALNY has a negative Return on Equity (-51.11%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Alnylam Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ALNY's short term assets ($1.9B) exceeds its short term liabilities ($352.9M)

Long Term Liabilities: ALNY's short term assets (1.9B) exceeds its long term liabilities (581.7M)


Debt to Equity History and Analysis

Debt Level: ALNY is debt free.

Reducing Debt: ALNY had no debt 5 years ago.


Balance Sheet

Inventory Level: ALNY has a high level of physical assets or inventory.

Debt Coverage by Assets: ALNY's debt is not covered by short term assets (assets are -3.3377038855559E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALNY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALNY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Alnylam Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

John Maraganore (56yo)

16.9yrs

Tenure

US$5,089,269

Compensation

Dr. John M. Maraganore, M.D., Ph.D. was an Advisor at Flex Pharma, Inc. Dr. Maraganore has been the Chief Executive Officer and Executive Director at Alnylam Pharmaceuticals, Inc. since December 2002. He h ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD5.09M) is below average for companies of similar size in the US market ($USD11.04M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.5yrs

Average Tenure

56yo

Average Age

Experienced Management: ALNY's management team is considered experienced (4.5 years average tenure).


Board Age and Tenure

5.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: ALNY's board of directors are considered experienced (5.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.


Management Team

  • John Maraganore (56yo)

    CEO & Executive Director

    • Tenure: 16.9yrs
    • Compensation: US$5.09m
  • Laurie Keating (65yo)

    Executive VP

    • Tenure: 5.2yrs
    • Compensation: US$5.31m
  • Barry Greene (56yo)

    President

    • Tenure: 11.9yrs
    • Compensation: US$2.99m
  • Akshay Vaishnaw (56yo)

    President of Research & Development

    • Tenure: 10.9yrs
    • Compensation: US$2.62m
  • Yvonne Greenstreet (56yo)

    Executive VP & COO

    • Tenure: 3.2yrs
    • Compensation: US$2.68m
  • Nereyda Garcia

    Global Head of Ethics & Compliance

    • Tenure: 3.8yrs
  • Jeff Poulton (51yo)

    Executive VP & CFO

    • Tenure: 0.3yrs
  • Kevin Fitzgerald

    Senior VP & Chief Scientific Officer

    • Tenure: 0.5yrs
  • Al Boyle

    Senior Vice President of Technical Operations

    • Tenure: 0yrs
  • Christine Lindenboom

    Vice President of Investor Relations & Communications

    • Tenure: 0yrs

Board Members

  • Mike Bonney (61yo)

    Independent Chairman

    • Tenure: 3.9yrs
    • Compensation: US$704.92k
  • Paul Schimmel (78yo)

    Member of the Scientific Advisory Board & Director

    • Tenure: 0yrs
    • Compensation: US$676.80k
  • John Maraganore (56yo)

    CEO & Executive Director

    • Tenure: 16.9yrs
    • Compensation: US$5.09m
  • David E. Pyott (66yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$672.42k
  • Phil Sharp (74yo)

    Co-Founder

    • Tenure: 17.4yrs
    • Compensation: US$697.42k
  • Thomas Tuschl

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marsha Fanucci (65yo)

    Independent Director

    • Tenure: 8.9yrs
    • Compensation: US$688.67k
  • Amy Schulman (58yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$684.92k
  • Phil Zamore

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mano Manoharan (66yo)

    Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board

    • Tenure: 4.1yrs

Company Information

Alnylam Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alnylam Pharmaceuticals, Inc.
  • Ticker: ALNY
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.129b
  • Shares outstanding: 111.49m
  • Website: https://www.alnylam.com

Number of Employees


Location

  • Alnylam Pharmaceuticals, Inc.
  • 300 Third Street
  • 3rd Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
DULDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
0HD2LSE (London Stock Exchange)YesCommon StockGBUSDMay 2004
ALNY *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004

Biography

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi ther ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 23:54
End of Day Share Price2019/11/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.